New advances in the pathogenesis and progression of Barrett's esophagus

Current Molecular Medicine

Volumn 14, Issue 1, 2014, Pages 58-68

  Streppel, M M ^a,b   Montgomery, E A ^a   Maitra, A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Barrett's esophagus; Esophageal adenocarcinoma; Hedgehog; Next generation sequencing; Notch; Origin; Wnt

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN 4; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN 8; INTERLEUKIN 1BETA; INTERLEUKIN 6; MUCIN 2; MUCIN 4; NEUROGENIN 1; NOTCH RECEPTOR; PEPTIDES AND PROTEINS; PROTEIN P63; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; UVOMORULIN; VILLIN; WNT INHIBITORY FACTOR 1; WNT PROTEIN; ALKALINE PHOSPHATASE; CYTOKERATIN; PROTEIN; PROTEIN PATCHED 1; PROTEIN SERINE THREONINE KINASE; SECRETED FRIZZLED RELATED PROTEIN 1; SMOOTHENED PROTEIN; TRANSCRIPTION FACTOR HES 1;

ARID1A GENE; BARRETT ESOPHAGUS; ESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL DYSPLASIA; GENE; GENE MUTATION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ARTICLE; BIOPSY; CAUCASIAN; CELL DIFFERENTIATION; COLUMNAR EPITHELIUM; DISEASE COURSE; DNA METHYLATION; GENE EXPRESSION; KERATINOCYTE; LOWER ESOPHAGUS SPHINCTER; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; NONSENSE MUTATION; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PHENOTYPE; PROTEIN LOCALIZATION; SQUAMOUS EPITHELIUM;

ANIMALS; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; SIGNAL TRANSDUCTION;

EID: 84891859095     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/15665240113139990068     Document Type: Review

References (106)

1. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: An endoscopic study. Gastroenterology 2005; 129(6): 1825-31.
2. Falk GW. Barrett's esophagus. Gastroenterology 2002; 122(6): 1569-91.
3. Guillem PG. How to make a Barrett esophagus: Pathophysiology of columnar metaplasia of the esophagus. Digest Dis Sci 2005; 50(3): 415-24.
4. Kahrilas PJ, Shaheen NJ, Vaezi M. American Gastroenterological Association institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135(4): 1392-413.
5. Miros M, Kerlin P, Walker N. Only Patients with Dysplasia Progress to Adenocarcinoma in Barrett-Esophagus. Gut 1991; 32(12): 1441-6.
6. Hameeteman W, Tytgat GNJ, Houthoff HJ, Vandentweel JG. Barretts Esophagus - Development of Dysplasia and Adenocarcinoma. Gastroenterology 1989; 96(5): 1249-56.
7. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33(9): 1155-8.
8. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92(2): 212-5.
9. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94(8): 2037-42.
10. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of Adenocarcinoma among Patients with Barrett's Esophagus. New Engl J Med 2011; 365(15): 1375-83.
11. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122(3): 633-40.
12. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002; 122(1): 26-33.
13. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356(9247): 2079-85.
14. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100(16): 1184-7.
15. Odze RD, Maley CC. Neoplasia Without Dysplasia Lessons From Barrett Esophagus and Other Tubal Gut Neoplasms. Arch Pathol Lab Med 2010; 134(6): 896-906.
16. Riddell RH, Odze RD. Definition of Barrett's Esophagus: Time for a Rethink-Is Intestinal Metaplasia Dead? Am J Gastroenterol 2009; 104(10): 2588-94.
17. Takubo K, Aida J, Naomoto Y, et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute barrett adenocarcinoma. Hum Pathol 2009; 40(1): 65-74.
18. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol 2008; 295(2): G211-8.
19. Wang X, Ouyang H, Yamamoto Y, et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 2011; 145(7): 1023-35.
20. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398(6729): 714-8.
21. Daniely Y, Liao G, Dixon D, et al. Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium. Am J Physiol Cell Physiol 2004; 287(1): C171-81.
22. Glickman JN, Chen YY, Wang HH, Antonioli DA, Odze RD. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am J Surg Pathol 2001; 25(5): 569-78.
23. Stairs DB, Nakagawa H, Klein-Szanto A, et al. Cdx1 and c-Myc Foster the Initiation of Transdifferentiation of the Normal Esophageal Squamous Epithelium toward Barrett's Esophagus. PLoS One 2008; 3(10): e3534.
24. Wang J, Qin R, Ma Y, et al. Differential gene expression in normal esophagus and Barrett's esophagus. J Gastroenterol 2009; 44(9): 897-911.
25. Quante M, Bhagat G, Abrams JA, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 2012; 21(1): 36-51.
26. Colleypriest BJ, Farrant JM, Slack JM, Tosh D. The role of Cdx2 in Barrett's metaplasia. Biochem Soc Trans 2010; 38(2): 364-9.
27. Eda A, Osawa H, Satoh K, et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 2003; 38(1): 14-22.
28. Hu YC, Williams VA, Gellersen O, Jones C, Watson TJ, Peters JH. The pathogenesis of Barrett's esophagus: Secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells. J Gastrointest Surg 2007; 11(7): 827-34.
29. Kazumori H, Ishihara S, Rumi MAK, Kadowaki Y, Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 2006; 55(1): 16-25.
30. Beck F, Chawengsaksophak K, Waring P, Playford RJ, Furness JB. Reprogramming of intestinal differentiation and intercalary regeneration in Cdx2 mutant mice. Proc Natl Acad Sci USA 1999; 96(13): 7318-23.
31. Silberg DG, Sullivan J, Kang E, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002; 122(3): 689-96.
32. Moons LM, Bax DA, Kuipers EJ, et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004; 57(10): 1063-8.
33. Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Modern Pathol 2004; 17(10): 1282-8.
34. Shi XY, Bhagwandeen B, Leong AS. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus. Am J Clin Pathol 2008; 129(4): 571-7.
35. van Baal JWPM, Bozikas A, Pronk R, et al. Cytokeratin and CDX-2 expression in Barrett's esophagus. Scand J Gastroenterol 2008; 43(2): 132-40.
36. Vaninetti N, Williams L, Geldenhuys L, Porter GA, Guernsey DL, Casson AG. Regulation of CDX2 Expression in Esophageal Adenocarcinoma. Mol Carcinog 2009; 48(10): 965-74.
37. Villanacci V, Rossi E, Zambelli C, et al. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasiacarcinoma progression in Barrett's esophagus. Digest Liver Dis 2007; 39(4): 305-11.
38. Huo XF, Zhang HY, Zhang XI, et al. Acid and Bile SaltInduced CDX2 Expression Differs in Esophageal Squamous Cells From Patients With and Without Barrett's Esophagus. Gastroenterology 2010; 139(1): 194-U297.
39. Burnat G, Rau T, Elshimi E, Hahn EG, Konturek PC. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. Scand J Gastroenterol 2007; 42(12): 1460-5.
40. Kazumori H, Ishihara S, Rumi MA, Kadowaki Y, Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 2006; 55(1): 16-25.
41. Liu T, Zhang X, So CK, et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis 2007; 28(2): 488-96.
42. Mutoh H, Hakamata Y, Sato K, et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice. Biochem Biophys Res Commun 2002; 294(2): 470-9.
43. Kong J, Crissey MA, Funakoshi S, Kreindler JL, Lynch JP. Ectopic Cdx2 expression in murine esophagus models an intermediate stage in the emergence of Barrett's esophagus. PLoS One 2011; 6(4): e18280.
44. Clemons NJ, Wang DH, Croagh D, et al. Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol 2012; 303(12): G1335-46.
45. Yin L, Velazquez OC, Liu ZJ. Notch signaling: Emerging molecular targets for cancer therapy. Biochem Pharmacol 2010; 80(5): 690-701.
46. Borggrefe T, Oswald F. The Notch signaling pathway: Transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009; 66(10): 1631-46.
47. Katoh M, Katoh M. Notch signaling in gastrointestinal tract (Review). Int J Oncol 2007; 30(1): 247-51.
48. Kopan R, Ilagan MXG. The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism. Cell 2009; 137(2): 216-33.
49. Wang ZW, Li YW, Banerjee S, Sarkar FH. Emerging role of Notch in stem cells and cancer. Cancer Lett 2009; 279(1): 8-12.
50. Shih IM, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007; 67(5): 1879-82.
51. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005; 435(7044): 964-8.
52. van Es JH, van Gijn ME, Riccio O, et al. Notch/gammasecretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435(7044): 959-63.
53. Yang Q, Bermingham NA, Finegold MJ, Zoghbi HY. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 2001; 294(5549): 2155-8.
54. Mendelson J, Song SM, Li Y, et al. Dysfunctional Transforming Growth Factor-beta Signaling With Constitutively Active Notch Signaling in Barrett's Esophageal Adenocarcinoma. Cancer 2011; 117(16): 3691-702.
55. Menke V, van Es JH, de Lau W, et al. Conversion of metaplastic Barrett's epithelium into post-mitotic goblet cells by gamma-secretase inhibition. Dis Model Mech 2010; 3(1-2): 104-10.
56. Tamagawa Y, Ishimura N, Uno G, et al. Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus. Laboratory Invest 2012; 92(6): 896-909.
57. Kong J, Crissey MA, Sepulveda AR, Lynch JP. Math1/Atoh1 contributes to intestinalization of esophageal keratinocytes by inducing the expression of Muc2 and Keratin-20. Dig Dis Sci 2012; 57(4): 845-57.
58. Morrow DJ, Avissar NE, Toia L, et al. Pathogenesis of Barrett's esophagus: Bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells. Surgery 2009; 146(4): 714-22.
59. Nehme R, Mus-Veteau I. Proteins of the Hedgehog signaling pathway as therapeutic targets against cancer. Expert Rev Proteomics 2010; 7(4): 601-12.
60. Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009; 30(6): 303-12.
61. Wetmore C. Sonic hedgehog in normal and neoplastic proliferation: insight gained from human tumors and animal models. Curr Opin Genet Dev 2003; 13(1): 34-42.
62. Katoh Y, Katoh M. Hedgehog signaling pathway and gastrointestinal stem cell signaling network (Review). Int J Mol Med 2006; 18(6): 1019-23.
63. Yang L, Xie G, Fan Q, Xie J. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010; 29(4): 469-81.
64. Merchant AA, Matsui W. Targeting Hedgehog - a Cancer Stem Cell Pathway. Clin Cancer Res 2010; 16(12): 3130-40.
65. Wang DH, Clemons NJ, Miyashita T, et al. Aberrant Epithelial-Mesenchymal Hedgehog Signaling Characterizes Barrett's Metaplasia. Gastroenterology 2010; 138(5): 1810-22.
66. Yamanaka Y, Shiotani A, Fujimura Y, et al. Expression of Sonic hedgehog (SHH) and CDX2 in the columnar epithelium of the lower oesophagus. Dig Liver Dis 2011; 43(1): 54-9.
67. Bastide P, Darido C, Pannequin J, et al. Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. J Cell Biol 2007; 178(4): 635-48.
68. Blache P, van de Wetering M, Duluc I, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 2004; 166(1): 37-47.
69. Mori-Akiyama Y, van den Born M, van Es JH, et al. SOX9 is required for the differentiation of paneth cells in the intestinal epithelium. Gastroenterology 2007; 133(2): 539-46.
70. Johnstone CN, Tebbutt NC, Abud HE, et al. Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2000; 279(3): G500-10.
71. Gibson MK, Zaidi AH, Davison JM, et al. Prevention of Barrett Esophagus and Esophageal Adenocarcinoma by Smoothened Inhibitor in a Rat Model of Gastroesophageal Reflux Disease. Ann Surg 2013; 258(1): 82-8.
72. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149(6): 1192-205.
73. Aguilera O, Fraga MF, Ballestar E, et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006; 25(29): 4116-21.
74. Nojima M, Suzuki H, Toyota M, et al. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 2007; 26(32): 4699-713.
75. Pinto D, Clevers H. Wnt, stem cells and cancer in the intestine. Biol Cell 2005; 97(3): 185-96.
76. Taniguchi H, Yamamoto H, Hirata T, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005; 24(53): 7946-52.
77. Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 2006; 25(21): 3084-92.
78. Clement G, Jablons DM, Benhattar J. Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets 2007; 11(3): 375-89.
79. van Dekken H, Hop WC, Tilanus HW, et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol 2008; 130(5): 745-53.
80. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998; 152(1): 135-44.
81. Bian YS, Osterheld MC, Bosman FT, Fontolliet C, Benhattar J. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000; 114(4): 583-90.
82. Falkenback D, Nilbert M, Oberg S, Johansson J. Prognostic value of cell adhesion in esophageal adenocarcinomas. Dis Esophagus 2008; 21(2): 97-102.
83. Krishnadath KK, Tilanus HW, van Blankenstein M, et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 1997; 182(3): 331-8.
84. Osterheld MC, Bian YS, Bosman FT, Benhattar J, Fontolliet C. Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. Am J Clin Pathol 2002; 117(3): 451-6.
85. Kadowaki T, Shiozaki H, Inoue M, et al. E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res 1994; 54(1): 291-6.
86. Corn PG, Heath EI, Heitmiller R, et al. Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenocarcinoma. Clin Cancer Res 2001; 7(9): 2765-9.
87. Wijnhoven BP, de Both NJ, van Dekken H, Tilanus HW, Dinjens WN. E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus. Br J Cancer 1999; 80(10): 1652-7.
88. Choi YW, Heath EI, Heitmiller R, Forastiere AA, Wu TT. Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas. Mod Pathol 2000; 13(10): 1055-9.
89. Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma 2008; 55(3): 165-76.
90. Bektas N, Donner A, Wirtz C, Heep H, Gabbert HE, Sarbia M. Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus. Am J Clin Pathol 2000; 114(6): 890-5.
91. Gonzalez MV, Artimez ML, Rodrigo L, et al. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 1997; 50(3): 212-7.
92. Ogasawara S, Maesawa C, Tamura G, Satodate R. Lack of Mutations of the Adenomatous Polyposis-Coli Gene in Esophageal and Gastric Carcinomas. Virchows Arch 1994; 424(6): 607-11.
93. Powell SM, Papadopoulos N, Kinzler KW, Smolinski KN, Meltzer SJ. Apc Gene-Mutations in the Mutation Cluster Region Are Rare in Esophageal Cancers. Gastroenterology 1994; 107(6): 1759-63.
94. Agrawal N, Jiao Y, Bettegowda C, et al. Comparative Genomic Analysis of Esophageal Adenocarcinoma and Squamous Cell Carcinoma. Cancer Discov 2012; 2(10): 899-905.
95. Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol 2006; 208(1): 100-7.
96. Clement G, Guilleret I, He B, et al. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci 2008; 99(1): 46-53.
97. Zou H, Molina JR, Harrington JJ, et al. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005; 116(4): 584-91.
98. Streppel MM, Lata S, Delabastide M, et al. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene 2013; Epub ahead of print.
99. Li M, Zhao H, Zhang X, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011; 43(9): 828-9.
100. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011; 43(12): 1219-23.
101. Wang S, Zhan M, Yin J, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006; 25(23): 3346-56.
102. Alvarez H, Opalinska J, Zhou L, et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet 2011; 7(3): e1001356.
103. Raskind WH, Norwood T, Levine DS, Haggitt RC, Rabinovitch PS, Reid BJ. Persistent Clonal Areas and Clonal Expansion in Barretts-Esophagus. Cancer Res 1992; 52(10): 2946-50.
104. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000; 60(18): 5021-6.
105. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001; 61(8): 3410-8.
106. Selaru FM, Zou T, Xu Y, et al. Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene 2002; 21(3): 475-8.